

1

2

3

4 **Cost-effectiveness analysis of COVID-19 booster doses**

5 **and oral antivirals in the Indo-Pacific**

6

7 Gizem Mayis Bilgin^{1*}, Syarifah Liza Munira², Kamalini Lokuge¹, Kathryn Glass¹

8

9 ¹ *National Centre for Epidemiology and Population Health, The Australian National University,*
10 *Canberra, Australia*

11 ² *Faculty of Economics and Business, Universitas Indonesia, Jakarta, Indonesia*

12

13 * *Corresponding author. E-mail address: gizem.bilgin@anu.edu.au (GMB)*

14

15 Abstract

16 **Background:** Decision-makers in middle-income countries need evidence on the cost-
17 effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these
18 healthcare interventions.

19
20 **Methods:** We used a dynamic transmission model to assess the cost-effectiveness of COVID-
21 19 booster doses and oral antivirals in Fiji, Indonesia, Papua New Guinea, and Timor-Leste.
22 We conducted cost-effectiveness analysis from both healthcare and societal perspectives
23 using 3% discounting for ongoing costs and health benefits. We developed an interactive R
24 Shiny which allows the user to vary key model assumptions, such as the choice of discounting
25 rate, and view how these assumptions affect model results.

26
27 **Findings:** Booster doses were cost saving and therefore cost-effective in all four middle-
28 income settings from both healthcare and societal perspectives using 3% discounting.
29 Providing oral antivirals was cost-effective from a healthcare perspective if procured at a low
30 generic (\$25 United States Dollars) or middle-income reference price (\$250 United States
31 Dollars); however, their cost-effectiveness was strongly influenced by rates of wastage or
32 misuse, and the ongoing costs of care for patients hospitalised with COVID-19. Interestingly,
33 the cost or wastage of rapid antigen tests did not appear strongly influential over the cost-
34 effectiveness of oral antivirals in any of the four study settings.

35
36 **Conclusions:** Our results support that government funded COVID-19 booster programs
37 continue to be cost-effective in middle-income settings. Oral antivirals demonstrate the
38 potential to be cost-effective if procured at or below a middle-income reference price of \$250
39 USD per schedule. Further research should quantify the rates of wastage or misuse of oral
40 COVID-19 antivirals in middle-income settings.

41

42 Introduction

43 Substantial population immunity has developed against coronavirus disease 2019 (COVID-
44 19), with seroprevalence levels in 2023 above 90% in most countries due to immunity from
45 previous infection or vaccination [1]. Three years after the emergence of COVID-19, vaccines
46 supplies have been sufficient for primary doses and partial booster dose coverage to reach
47 low- and middle-income nations [2]. Still, older adults and individuals with comorbidities remain
48 at considerable risk of severe outcomes associated with COVID-19 [3-5].

49
50 The World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization
51 (SAGE) roadmap for the use of COVID-19 vaccines (updated March 2023) urges policymakers
52 in low- and middle-income countries to reevaluate the funding of COVID-19 interventions in
53 the context of substantial population immunity against COVID-19 [3]. In a previous paper, we
54 constructed a dynamic transmission model to estimate the impact of oral antivirals and booster
55 doses on the burden of disease in Fiji, Indonesia, Timor-Leste, and Papua New Guinea – four
56 middle-income nations with varying vaccine coverage, vaccine hesitancy, prevalence of
57 comorbidities, and age structure. The model found that booster doses had the largest
58 population-level impact in settings with high vaccine acceptance, and oral antivirals had the
59 largest population-level impact in settings with lower vaccine acceptance [6]. This modelling
60 provided evidence for the continued provision of booster doses to high-risk adults, and
61 increased access to oral antivirals in low- and middle-income settings. However, the feasibility
62 of delivering further booster doses and/or oral antivirals will depend on their cost-effectiveness
63 and relative opportunity costs compared to other healthcare priorities.

64
65 This paper examines whether COVID-19 booster doses and oral antivirals are cost-effective
66 from healthcare and societal perspectives in Fiji, Indonesia, Papua New Guinea, and Timor-
67 Leste. We explore various combinations of booster dose and oral antiviral eligibility. We model
68 an annual booster dose campaign with and without the year-round provision of oral antivirals

69 to symptomatic adults at highest risk of severe COVID-19 outcomes. This paper seeks to
70 answer (1) Whether annual booster programs are cost-effective in middle-income settings; (2)
71 Whether oral antiviral programs have the potential to be cost-effective in middle-income
72 settings; and (3) What factors are most influential over whether booster dose and oral antiviral
73 programs are cost-effective in middle-income settings?

74

75 **Methods**

76 **Study design**

77 We evaluated the cost-effectiveness of COVID-19 booster dose and oral antiviral programs
78 during 2023. Our comparator for this analysis was the continuation of existing primary and
79 booster vaccine programs without oral antivirals and without further booster doses. The
80 epidemiological impacts of COVID-19 booster doses and oral antivirals were quantified in a
81 previous mathematical modelling paper [6]. Here, we estimate the cost of administering
82 COVID-19 booster doses, the cost of delivering oral COVID-19 antivirals, and the costs
83 averted by either intervention. We present our analyses from both a societal and healthcare
84 perspectives. Our main inclusion from the societal perspective was the cost of lost productivity
85 due to illness and premature death. We applied standard 3% discounting to costs and health
86 outcomes. All prices were adjusted to 2022 United States Dollars (USD) using the International
87 Monetary Fund's gross domestic product (GDP) deflators [7], as per [8].

88

89 We estimated the impact of booster doses and oral antivirals on the incidence of severe
90 disease over the time horizon of one year. We included the ongoing health outcomes and
91 productivity losses associated with severe disease occurring within this one-year time horizon;
92 these ongoing effects were discounted by 3%. The choice to use a time horizon of one year
93 aligned with existing economic modelling for COVID-19, see systematic review [9]. A one-year
94 time horizon was appropriate for the evaluation of oral antivirals since the effects of oral
95 antivirals are short-term and localised to the individual receiving the antivirals. A one-year time

96 horizon was conservative but appropriate for the evaluation of booster doses since the
97 increased protection against severe outcomes provided by booster doses compared to
98 previous vaccination was expected to wane after one year [10].

99

100 **Health outcomes**

101 **Disease model**

102 The details of the deterministic COVID-19 transmission model and stochastic severe outcome
103 projections have been described in previous papers [6, 11], and a summary is provided in S1
104 Underlying Dynamic Transmission Model. In brief, we constructed a Susceptible-Exposed-
105 Infected-Recovered (SEIR) model stratified by age, comorbidities, and vaccination status. This
106 model was fit to the immunity profile of four study settings: Fiji, Indonesia, Papua New Guinea,
107 and Timor-Leste (comparison of setting characteristics provided in Table S1.1). We modelled
108 the provision of further booster doses and/or oral antivirals and estimated the number of doses
109 needed to prevent one hospitalisation or death. Severe adverse outcomes associated with the
110 use of vaccines or oral antivirals were not included in the model since there was insufficient
111 documentation of these events in available literature.

112

113 **Target population**

114 We considered multiple eligibility criteria for booster doses and oral antivirals. We considered
115 scenarios without booster doses, with booster doses for high-risk adults, with booster doses
116 for all adults, and with booster doses for adults who have received their primary schedule but
117 not yet received a booster ('catch-up' campaigns). We assumed that oral antivirals would be
118 given only to symptomatic adults at high risk of severe disease. We identified 'high-risk adults'
119 as adults aged 18-59 with a known comorbidity and all adults aged over 60, as per current
120 WHO Guidelines for delivery of COVID-19 antivirals and vaccines [3, 12]. We included
121 additional scenarios for the provision of antivirals to unvaccinated adults in the Supplementary

122 Material since the WHO guidelines list an absence of COVID-19 vaccination as an additional
123 risk factor to consider when dispensing oral antivirals [12].

124

125 **Translating health outcomes to QALYs**

126 We calculated quality-adjusted life years (QALYs) saved by booster doses and/or oral
127 antivirals by considering the number of deaths prevented, and incidence of nonfatal mild,
128 severe, and critical COVID-19 averted. We adapted estimates by Robinson, Eber & Hammitt
129 (2022) to translate the incidence of mild, severe, and critical COVID-19 to QALYs [13] (Table
130 S2.1). This study by Robinson et al. considered the duration of symptoms and health-related
131 quality of life (HRQoL) of nonfatal symptomatic cases. We converted deaths prevented into
132 QALYs using life expectancy at each age from United Nations World Prospect Population
133 estimates for 2022 [14], adjusted by the same age-specific HRQoL estimates as in [13]. We
134 considered QALYs associated with long COVID for additional sensitivity analyses presented
135 in S4.7 of the Supplementary Material.

136

137 **Intervention costs**

138 We used United Nations Children's Fund (UNICEF) Supply Division price data to estimate the
139 price per dose of COVID-19 vaccines, syringes, and safety boxes. All four study settings are
140 eligible for the COVAX Advance Market Commitment [15]. We assumed that Indonesia, Timor-
141 Leste, and Fiji used Moderna, and Papua New Guinea used Johnson & Johnson for future
142 booster programs based on their previous vaccination history [16]. UNICEF prices for both
143 vaccine doses and injection equipment are listed as free carrier prices, meaning that they
144 include freight costs.

145

146 We estimated the operational cost per booster dose using a meta-analysis estimate of routine
147 immunisation delivery costs in low- and middle-income countries [17]. Our sensitivity analysis
148 was bounded by the minimum and maximum estimates of routine immunisation delivery costs

149 included in this meta-analysis. Costs previously reported for supplementary immunisation
150 activities and mass drug administration campaigns in our study settings (\$0.33-\$2.60 [18-21])
151 fell within the range in which we conducted sensitivity analysis. Previous routine immunisation
152 programs for adults in our study settings have been limited to tetanus toxoid vaccination of
153 pregnant mothers [22], and a recommendation for influenza vaccination in Indonesia for
154 individuals intending to participate in a Hajj pilgrimage (<0.2% coverage) [23].

155
156 We used COVAX estimates for the wastage rates of COVID-19 vaccine doses. Data on
157 country-specific COVID-19 vaccine wastage rates were not available [24]. We included
158 sensitivity analysis informed by the range of wastage rates reported for routine vaccines in our
159 study settings [18-20]. WHO targets for acceptable wastage targets are 5% for double-dose
160 vials and 15% for multi-dose vials in the third year of introduction [25].

161
162 We assessed the cost-effectiveness of oral antivirals at three schedule prices: a high-income
163 country reference price of \$530 USD [26], a middle-income reference price of \$250 USD [27],
164 and the anticipated low generic price of \$25 USD [28]. We assumed that antiviral prices would
165 be free carrier prices, as per previous agreements for the delivery of vaccine doses and
166 injection equipment to low- and middle-income countries.

167
168 We estimated the number of rapid antigen tests (RATs) used for every schedule of oral
169 antivirals (wastage factor) by considering the expected proportion of acute respiratory
170 illnesses (ARI) attributable to COVID-19, and the likelihood of a case testing positive on a
171 RAT. We assumed that the proportion of ARI attributable to COVID-19 would be similar to the
172 proportion of influenza-like illness attributable to influenza prior to the introduction of COVID-
173 19 (30%) [29], and included sensitivity analysis for lower (15%) and higher (60%) attributable
174 fractions. Estimates from Menkir and colleagues informed the likelihood of a symptomatic case
175 testing positive on a RAT within the treatment window (53.7%, 95% CI 27.1%-72.6%) [30].
176 Together, this data led to an estimate of six RAT tests (lower = 3, upper = 12) for every

177 schedule of oral antivirals being dispensed. We assumed a home-based testing system where
178 individuals tested at home before presenting to healthcare to receive oral antivirals.

179

180 **Table 1. Parameters informing booster dose and oral antiviral program costs.** All costs reported
181 in 2022 United States Dollars (USD).

Parameter	Component	Estimate	Source
Cost of vaccine	Price per dose	\$1.50 – Johnson & Johnson \$0.70 – Moderna	UNICEF Supply Division COVID-19 vaccine price data [31]
	Wastage rate	10% Sensitivity analysis: 0%-50%	COVAX estimate for the expected wastage rate of COVID-19 vaccines [32], range informed by wastage rates of routine vaccines [18-20]
Injection equipment	Price per syringe and 1/100 safety box	\$0.0351	UNICEF Supply Division syringe and safety box bundles price data [33]
	Wastage rate	10%	WHO guidelines for the introduction of new vaccines [34]
Operational costs (vaccine)	All other costs including cost of personnel, training, transport etc.	\$2.85 Sensitivity analysis: \$0.21-\$13.04	Meta-analysis of routine immunisation delivery costs in low- and middle-income countries [17]
Cost of antiviral	Price per schedule	\$530 USD high-income reference price \$250 USD middle-income reference price \$25 USD low generic cost	United States of America government agreement [26] Malaysian government agreement [27] Pfizer agreement for low- and middle-income countries, notably excluding Fiji [28]
	Wastage rate	0% Sensitivity analysis: 0-60%	Not considered in previous cost-effectiveness studies [35-37], range informed by an estimate for the proportion of overprescribed or inappropriately dispensed antimicrobials in middle-income countries [38]

Rapid antigen tests	Price per test	\$2.225	Median price across products listed on UNICEF catalogue [39]
	Wastage factor	6 Sensitivity analysis: 3-12	Estimate informed by distribution of influenza-like illness attributable to influenza [29] and likelihood of a COVID-19 positive individual testing positive on a rapid antigen test within the treatment window [30]
Operational costs (antiviral)	Price per outpatient visit for individual to be prescribed oral antivirals	\$4.36 – Fiji \$2.57 – Indonesia \$3.91 – Papua New Guinea \$1.83 – Timor-Leste	WHO CHOICE estimates for the cost per outpatient visit to a health centre with no beds [40]

182

183 **Healthcare and productivity costs averted**

184 We calculated direct medical costs averted by preventing hospital admissions (inpatient
185 costs), reducing the incidence of non-hospitalised symptomatic disease (outpatient costs), and
186 reducing hospital length of stay (Table 2). Inpatient costs were estimated using the analysis
187 by Nugraha et al. of COVID-19 inpatient costs recorded by the Indonesian Ministry of Health
188 [41]. No primary data were available for our other three study settings. Instead, we adapted
189 estimates from Indonesia to other study settings by fixing the costs of drugs and consumables,
190 and adjusting the costs of healthcare workers' fees, accommodation, medical procedures,
191 medical tests and examinations, and medical devices. These costs were adjusted by
192 comparing WHO CHOICE estimates for the cost of inpatient bed days without drugs in
193 international dollars between settings.

194

195 We made a conservative estimate for outpatient costs averted by using the lowest cost listed
196 for outpatient care in WHO CHOICE estimates. Where available, we used setting-specific
197 estimates on healthcare seeking behaviours of adults for mild respiratory illnesses (Table 2).
198 There were no data available for Papua New Guinea, so we assumed equal health seeking
199 rates to Indonesia. Sensitivity analysis revealed that outpatient costs, and subsequently our

200 estimates for health seeking rates, were not highly influential over the cost-effectiveness of
201 either booster doses or oral antivirals.

202

203 We estimated healthcare savings due to the reduced length of stay of patients hospitalised
204 after receiving oral antivirals. We did not estimate costs saved due to reduced lengths of stay
205 of patients who had received additional booster doses. Evidence supports that vaccination
206 reduces the length of stay in a general ward [42, 43] and in an intensive care unit (ICU) [44],
207 but the effect of recent booster doses on length of stay have not yet been quantified.

208

209 We were not able to include direct non-medical costs in accessing healthcare – such as the
210 cost of transportation, meals and care provided by family – due to an absence of data. A
211 systematic review of paediatric infectious diseases in low- and middle-income countries found
212 that direct non-medical costs of accessing care ranged between \$1.21-\$28.29 for inpatients
213 and \$0-\$8.94 outpatients (2018 USD) [45]. Hence the inclusion of this variable is unlikely to
214 have a qualitative difference in the cost-effectiveness of either booster doses or oral antivirals
215 from a societal perspective.

216

217 Productivity losses due to illness and premature death were estimated using a human capital
218 approach – valuing lost time using an individual's gross earnings [46]. Productivity losses per
219 outcomes, age group and setting are presented in Table S2.2. We estimated productivity
220 losses due to premature death by considering years of life lost per age group and expected
221 earnings in future years [14]. Expected earnings were estimated using setting- and age-
222 specific labour force participation rates and annual outputs per worker modelled by the
223 International Labour Organization [47]. We estimated productivity losses due to illness by
224 considering Danish data on time taken to return to work after infection [48]; Danish data on
225 return to work after COVID-19 infection was more granular and aligned with other available
226 data from China and the Netherlands [49, 50].

227

228 **Table 2. Parameters estimating healthcare costs associated with COVID-19.** All costs reported in
 229 2022 United States Dollars.

Component	Estimate	Source
Cost per hospital admission	\$7,999.82 – Fiji	[41]
	\$5,847.48 – Indonesia	
	\$3,858.55 – Papua New Guinea	
	\$3,081.46 – Timor-Leste	
Cost per outpatient visit	\$4.36 – Fiji	[40]
	\$2.57 – Indonesia	
	\$3.91 – Papua New Guinea	
	\$1.83 – Timor-Leste	
Proportion of non-hospitalised symptomatic individuals accessing healthcare	81.6% – Fiji	[51-53]
	70.0% – Indonesia	
	70.0% – Papua New Guinea	
	76.6% – Timor-Leste	
Reduced length of stay of patients who received oral antivirals	0.784 days	[54]
Cost per extra day hospital length of stay	10%	[41]

230

231 **Sensitivity analysis to characterise uncertainty**

232 We conducted both deterministic and probabilistic sensitivity analysis to understand how
 233 different model parameters influenced the cost-effectiveness of booster doses and oral
 234 antivirals. Deterministic sensitivity analysis – visualised in a tornado plot – was conducted by
 235 running the model with the lower and upper estimates of each parameter whilst keeping all
 236 other parameters constant. Probabilistic sensitivity analysis was conducted by running the
 237 cost-effectiveness model one thousand times whilst randomly drawing from normal and
 238 lognormal distributions fit to the uncertainty of model parameters (Table S2.3). The
 239 corresponding one thousand incremental cost and one thousand incremental health effect
 240 values were visualised on an incremental cost-effectiveness plane to represent the uncertainty

241 in our model. We also calculated the likelihood of interventions being cost-effective at varying
242 willingness-to-pay thresholds using the one thousand stochastic simulations.

243

244 **Access to interactive results and breakdown of parameter effects**

245 We provide an interactive R Shiny for viewing and interacting with this paper's results on
246 https://gizemmayisbilgin.shinyapps.io/indoPacific_COVID19_costEffectivenessAnalysis/ or
247 available directly for download

248 [https://github.com/gizembilgin/indoPacific_COVID19_cost_effectiveness/tree/main/03_cost](https://github.com/gizembilgin/indoPacific_COVID19_cost_effectiveness/tree/main/03_cost_effectiveness_analysis/07_shiny)

249 [effectiveness_analysis/07_shiny](https://github.com/gizembilgin/indoPacific_COVID19_cost_effectiveness/tree/main/03_cost_effectiveness_analysis/07_shiny). The Shiny allows a user to vary key model assumptions,
250 such as the discounting rate, and see how this affects the paper's results. The Shiny
251 includes expected incremental cost-effectiveness ratios with 95% prediction intervals for all
252 scenarios presented in Figs 1 and 2. A static overview of net outcomes and costs with
253 corresponding incremental costs and benefits is provided in Tables S3.1 and S3.2. QALYs
254 averted, intervention costs, healthcare costs averted, and productivity losses prevented by
255 the source of these incremental differences is provided in Figures S3.1 and S3.2.

256

257 **Results**

258 **Cost-effectiveness of booster doses**

259 Annual booster programs were cost saving and therefore cost-effective from both healthcare
260 and societal perspectives in all study settings and under all eligibility criteria (Fig 1). Programs
261 which provided booster doses to all adults were estimated to be more cost-saving than booster
262 programs which provided booster doses to high-risk adults only, particularly from a societal
263 perspective. Differences in the incremental costs and benefits of catch-up campaigns varied
264 by the vaccination history of the study setting. For example, a catch-up campaign in Indonesia
265 averted a similar number of QALYs but prevented lower productivity costs than a campaign
266 which provided booster doses to all adults. This was because prior booster coverage was

267 higher in younger adults than older adults, so a catch-up campaign would provide more
268 booster doses to older adults (group at highest risk of severe outcomes) and less doses to
269 younger adults (group with highest productivity losses). By comparison, in Fiji, there was little
270 difference in vaccine uptake by age, so a catch-up campaign averted a higher number of
271 QALYs and prevented larger productivity costs than a campaign which provided booster doses
272 to all adults.

273

274 Deterministic sensitivity analysis supported that providing booster doses to all adults would be
275 cost saving and therefore cost-effective using the lower and upper estimates of all model
276 parameters (Figures S4.1 and S4.2). The only exception was in Timor-Leste, where a booster
277 dose program for all adults had an expected mean cost of \$388 per QALY averted when using
278 the upper bound estimate for the operational cost of delivering booster doses. This program
279 would still be cost-effective using Timor-Leste's GDP per capita (\$2,358) as a threshold.

280

281 The cost of caring for patients hospitalised due to COVID-19 had the largest influence over
282 the cost-effectiveness of booster doses in most settings from a healthcare perspective (Figure
283 S4.1). Productivity losses due to illness had the largest influence on the cost-effectiveness of
284 booster doses from a societal perspective (Figure S4.2). Booster wastage rates and the cost
285 of injection equipment did not have a large influence over the cost-effectiveness of booster
286 doses from either a societal or healthcare perspective. The order of the importance of other
287 parameters – most notably, the operational cost of delivering booster doses – varied across
288 settings.

289

290 **Fig. 1 Comparison of the incremental benefits (QALYs) and incremental costs of booster doses**
291 **in 2023.** Results are presented from both healthcare and societal perspectives using 3% discounting
292 of ongoing costs and health benefits and assuming no oral antivirals are available in the study settings.
293 Each point represents one simulation. One thousand simulations are represented for each booster
294 eligibility scenario and choice of perspective.

295

296 **Cost-effectiveness of oral antivirals**

297 Oral antiviral programs for high-risk adults demonstrated the potential to be cost-effective in
298 all settings using Pfizer's agreed low generic price, was also cost-effective in three settings
299 (not Timor-Leste) using the middle-income reference price, and in one setting (Papua New
300 Guina) using the high-income reference price from a healthcare perspective with GDP per
301 capita as a threshold for cost-effectiveness (Fig 2). In comparison, from a societal perspective,
302 providing oral antivirals to high-risk adults was cost saving in three settings (not Timor-Leste),
303 and cost-effective in all settings even when using the high-income reference price (Figure
304 S4.5).

305

306 The cost of oral antivirals per schedule, antiviral wastage rates, and the cost of care for
307 patients hospitalised due to COVID-19 were the three primary drivers of whether oral antivirals
308 were cost-effective from a healthcare perspective (Figure S4.3). Productivity losses due to
309 illness had a larger influence than productivity losses due to death over the cost-effectiveness
310 of oral antivirals from a societal perspective (Figure S4.4). Interestingly, the price or wastage
311 of RATs did not appear strongly influential over the cost-effectiveness of oral antivirals in any
312 of the four study settings. If the wastage of oral antivirals was high, oral antivirals could only
313 be cost-effective if procured at the low generic price in all study settings from a healthcare
314 perspective (Figure S4.8).

315

316 Oral antiviral programs for unvaccinated adults would only be cost-effective if procured at the
317 low generic price from a healthcare perspective (Figure S4.6). Indonesia was the only setting
318 where an oral antiviral program for unvaccinated individuals would be cost-effective if
319 purchased at the middle-income reference price. This was due to Indonesia's relative high
320 GDP per capita and lower vaccine coverage in older adults. Interestingly, providing oral
321 antivirals to all symptomatic adults would be cost-effective if a large supply of oral antivirals

322 was available at the low generic reference price (Figure S4.6). An oral antiviral with lower
323 effectiveness, as seen with molnupiravir, would only be cost-effective from a healthcare
324 perspective if the antiviral were available at the low generic cost (Figures S4.7).

325

326 **Fig. 2 Comparison of the probability of an oral antiviral being cost-effective by willingness to**
327 **pay USD per QALY thresholds across three antiviral schedule prices and three booster eligibility**
328 **strategies from a healthcare perspective.** Probabilities have been calculated as a % of one thousand
329 simulations. All scenarios assume that nirmatrelvir-ritonavir type oral antivirals are provided to
330 symptomatic high-risk adults and use 3% discounting of ongoing costs and health benefits. The dashed
331 line represents the nation's gross domestic product per capita as a possible threshold for cost-
332 effectiveness.

333

334 **Cost-effectiveness of oral antiviral – booster dose combinations**

335 Providing booster doses to all adults and oral antivirals to high-risk adults appeared cost-
336 effective in all study settings from both a healthcare and societal perspective at all antiviral
337 schedule prices using the nations' GDP per capita as a cost-effectiveness threshold (Fig 2).
338 Further, this combination strategy appeared cost saving from a healthcare perspective using
339 either the low-generic or middle-income reference prices for oral antivirals, and cost saving
340 from a societal perspective using all antiviral reference prices. The three parameters which
341 had the largest influence over the cost-effectiveness of a combination strategy from a
342 healthcare perspective were the cost of oral antivirals per schedule, antiviral wastage rates,
343 and the cost of care for patients hospitalised due to COVID-19 – i.e., the same parameters
344 which had the largest influence over the cost-effectiveness of a stand-alone oral antiviral
345 program.

346

347 **Fig. 3 Tornado plot visualising one-way deterministic sensitivity analysis of the cost-**
348 **effectiveness of providing booster doses to all adults and oral antivirals to high-risk adults in**
349 **2023 from a healthcare perspective.** Individual deterministic sensitivity analysis for the effects of

350 providing booster doses to all adults and oral antivirals to high-risk adults are provided in Figure S4.1
351 and S4.3 respectively. The dashed line represents the nation's gross domestic product (GDP) per capita
352 as a possible threshold for cost-effectiveness.

353

354 Discussion

355 Annual COVID-19 booster programs demonstrate a strong potential to be cost-effective in
356 middle-income settings. Providing oral antivirals to high-risk adults is also likely to be cost-
357 effective from a healthcare perspective if antivirals can be procured at appropriate prices. This
358 strategy is certainly cost-effective at Pfizer's agreed low generic price, and highly likely to be
359 cost-effective at our middle-income reference price (Malayasia's negotiated price). The price
360 or wastage of RATs was not influential over the cost-effectiveness of an oral antiviral program;
361 however, the wastage rate of oral antivirals was of concern from a healthcare perspective.
362 The choice of discounting did not affect whether an intervention was cost-effective. Most
363 interventions were cost-effective from a societal perspective.

364

365 Findings on the cost-effectiveness of booster doses and oral antivirals were fairly consistent
366 across the four study settings. The impact of different booster dose and antiviral programs on
367 the burden of disease varied across study settings due to prior vaccine coverage, prevalence
368 of comorbidities, and age-structure; however, qualitative decisions on which eligibility
369 strategies were cost-effective and the order of parameter importance in dictating cost-
370 effectiveness were largely consistent between study settings. Timor-Leste was least similar to
371 the three other settings due to its lower GDP per capita, relatively young population, and lower
372 prevalence of comorbidities.

373

374 Our analysis suggests that the cost-effectiveness of oral antivirals may depend on the rates
375 of antiviral wastage or misuse. Wastage rates for antivirals will include courses dispensed
376 which are unused, courses dispensed for individuals who do not have COVID-19 (false

377 positives and patients with other respiratory illnesses), courses which expire before
378 prescription, and courses dispensed too late to be effective. Neither high- nor middle-income
379 countries have publicly released rates of COVID-19 oral antiviral wastage or misuse at the
380 time of this study. This may be due to the political sensitivity surrounding this data and/or the
381 relative novelty of oral antivirals in these settings. It will be important to measure and monitor
382 the rates of antiviral wastage when oral antiviral programs are implemented in middle-income
383 countries.

384

385 Negotiations on appropriate oral antiviral prices for middle-income countries will be key in their
386 cost-effectiveness. The WHO believes that a lack of price transparency in deals with
387 pharmaceutical companies has made accessing oral antivirals a major challenge for low- and
388 middle-income countries [55]. We used three reference prices throughout our analysis – a low
389 generic price based on Pfizer’s commitment [28], a middle-income reference price based on
390 Malaysian government documentation [27], and a high-income reference price based on the
391 United States of America’s publicly released agreement [26]. Our results demonstrated that
392 oral antivirals will be cost-effective if procured at a low generic or middle-income reference
393 prices. Of our study settings, Indonesia, Papua New Guinea and Timor-Leste (not Fiji) are
394 eligible for Pfizer’s low price generics [56]. Pooled procurement mechanisms have already
395 achieved price reductions of 30-50% for diagnostic tests and between 10-50% on oxygen for
396 low- and middle-income countries over the course of the pandemic [57]. Further, 38 generic
397 manufacturers in 13 countries – 11 being low- and middle-income countries – have been
398 signed for nirmatrelvir-ritonavir [57]. If production is implemented at scale, there should be
399 sufficient supply to cover the needs of low- and middle-income countries. Pooled procurement
400 mechanisms and the scaling up of generic manufacturing should enable oral antivirals to be
401 accessed at cost-effective prices in middle-income settings.

402

403 Our results are comparable to similar studies, although there have been a limited number of
404 studies published on the cost-effectiveness of oral antivirals or booster doses in low- and

405 middle-income countries. A recent systematic review on the cost-effectiveness of COVID-19
406 vaccines noted a gap in published literature on the cost-effectiveness of booster doses [58]
407 (June 2023). Our results align with available studies which demonstrate that booster doses
408 appear cost saving in middle and high-income settings [59-61]. Previous studies have
409 demonstrated that providing nirmatrelvir-ritonavir to high-risk adults would be cost-effective in
410 high-income settings [36, 62, 63]. We identified only one study considering the cost-
411 effectiveness of oral antivirals in low- or middle-income countries (in preprint [64]). This study
412 demonstrated that nirmatrelvir-ritonavir was cost-saving when provided to older adults in
413 Rwanda, Zambia, and Ghana at Pfizer's low generic price. The study identified the price of
414 antivirals and the costs of hospitalisation as key determinants of the cost-effectiveness of oral
415 antivirals, aligning with our deterministic sensitivity analysis. Future work should consider
416 extending the wealth of modelling on epidemiological impact to also include an assessment of
417 the cost-effectiveness of oral antivirals and booster doses. This will better allow decision-
418 makers to compare these interventions against other healthcare priorities.

419
420 A key limitation in the applicability of our findings is uncertainty in pharmaceutical supplies and
421 ongoing health workforce capacity to deliver COVID-19 interventions. Theoretically, providing
422 booster doses to all adults and oral antivirals to all symptomatic adults appeared cost saving
423 in all study settings from a healthcare perspective if oral antivirals were procured at Pfizer's
424 low generic price. However, such a large program would require sufficient supplies of
425 pharmaceuticals, appropriate storage capacity, dedicated health workforce capacity, and
426 investment in surveillance programs to monitor vaccine effectiveness and antiviral resistance.
427 Three years into the pandemic, decision-makers have begun to compare the opportunity cost
428 of investing in COVID-19 interventions against other healthcare priorities [3].

429
430 Our study has several limitations due to the availability or timeliness of data informing model
431 parameters. The cost of inpatient care had a considerable influence on the cost-effectiveness
432 of both booster doses and oral antivirals in our analysis. Estimates for the cost of caring for

433 patients hospitalised with COVID-19 were from data collected during 2020 and 2021 [41].
434 Changing standards of care, such as reduced requirements for isolation, may reduce these
435 costs over time. Productivity losses due to illness had a substantial impact on the cost-
436 effectiveness of both interventions from a societal perspective. We used estimates on the time
437 taken to return to work after COVID-19 from a Danish study since no data were available from
438 comparable middle-income contexts. Delays in returning to work may be longer (lower access
439 to healthcare) or shorter (greater financial need) in low- and middle-income settings. Hence,
440 the characterisation of this parameter should be prioritised if cost-effectiveness analysis is to
441 be conducted from a societal perspective. There remains limited data on the ongoing
442 healthcare costs and productivity losses associated with long COVID, hence, we were unable
443 to include long COVID in our main analysis. Cost-effectiveness analysis of COVID-19 booster
444 doses and oral antivirals should be updated as timelier, and more setting-relevant data
445 emerges.

446

447 **Conclusions**

448 Our study supports the continued provision of booster doses as the most cost-effective
449 intervention against COVID-19. Our results demonstrate the potential for oral antivirals to also
450 be cost-effective if procured at reasonable prices for middle-income settings and implemented
451 with low wastage. Future rollout of both interventions should monitor their wastage rates, the
452 cost of care for patients hospitalised with COVID-19, and emerging evidence on the impacts
453 of long COVID to continue to determine their cost-effectiveness compared to the opportunity
454 costs of investing in other healthcare interventions.

455

456 **Data Availability Statement:** All data was collated from publicly available sources. Our
457 model code and inputs can be viewed on GitHub:

458 https://github.com/gizembilgin/indoPacific_COVID19_cost_effectiveness/tree/main. An

459 interactive R Shiny version of the results can be found hosted on

460 https://gizemmayisbilgin.shinyapps.io/indoPacific_COVID19_costEffectivenessAnalysis/ or

461 directly downloaded from

462 https://github.com/gizembilgin/indoPacific_COVID19_cost_effectiveness/tree/main/03_cost

463 [effectiveness_analysis/07_shiny](https://github.com/gizembilgin/indoPacific_COVID19_cost_effectiveness/tree/main/03_cost_effectiveness_analysis/07_shiny)

464 **Funding:** This research did not receive any specific funding.

465 **Competing Interests:** The authors declare that they have no competing interests.

466 **Author Contributions:** Conceptualisation – GMB, SLM, KL, KG; Methodology – GMB, SLM;

467 Formal analysis, investigation, software, and visualisation – GMB; Validation – KG; Writing

468 original draft – GMB; Writing review and editing - GMB, SLM, KL, KG.

469

470 **References**

471 1. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a
472 global SARS-CoV-2 seroprevalence dashboard. *The Lancet Infectious Diseases*.
473 2021;21(4):e75-e6. doi: 10.1016/S1473-3099(20)30631-9.

474 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
475 real time. *Lancet Infect Dis*. 2020;20(5):533-4. doi: 10.1016/S1473-3099(20)30120-1.

476 3. World Health Organization. WHO SAGE roadmap on uses of COVID-19 vaccines in
477 the context ofOMICRON and substantial population immunity: an approach to optimize the
478 global impact of COVID-19 vaccines at a time when Omicron and its sub-lineages are the
479 dominant circulating variants of concern, based on public health goals, evolving
480 epidemiology, and increasing population-level immunity, first issued 20 October 2020,
481 updated: 13 November 2020, updated: 16 July 2021, update: 21 January 2022, latest
482 update: 30 March 2023. Geneva: World Health Organization, 2023 Contract No.:
483 WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2023.1.

484 4. Sasanami M, Fujimoto M, Kayano T, Hayashi K, Nishiura H. Projecting the COVID-
485 19 immune landscape in Japan in the presence of waning immunity and booster vaccination.
486 *Journal of Theoretical Biology*. 2023;559:111384. doi: 10.1016/j.jtbi.2022.111384.

487 5. Adams K, Riddles JJ, Rowley EAK, Grannis SJ, Gaglani M, Fireman B, et al. Number
488 needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated
489 hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–

- 490 February 2022, VISION Network: a retrospective cohort study. *Lancet Regional Health -*
491 *Americas*. 2023;23. doi: 10.1016/j.lana.2023.100530.
- 492 6. Bilgin GM, Lokuge K, Munira SL, Glass K. Assessing the potential impact of COVID-
493 19 booster doses and oral antivirals: A mathematical modelling study of selected middle-
494 income countries in the Indo-Pacific. *Vaccine: X*. 2023;15:100386. doi:
495 10.1016/j.jvacx.2023.100386.
- 496 7. International Monetary Fund. *World Economic Outlook Database: April 2023* 2023
497 [Cited 12/04/2023]. Available from: [https://www.imf.org/en/Publications/WEO/weo-](https://www.imf.org/en/Publications/WEO/weo-database/2023/April)
498 [database/2023/April](https://www.imf.org/en/Publications/WEO/weo-database/2023/April).
- 499 8. Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for Inflation and
500 Currency Changes Within Health Economic Studies. *Value Health*. 2019;22(9):1026-32. doi:
501 10.1016/j.jval.2019.03.021.
- 502 9. Izadi R, Hatam N, Baberi F, Yousefzadeh S, Jafari A. Economic evaluation of
503 strategies against coronavirus: a systematic review. *Health Economics Review*.
504 2023;13(1):18. doi: 10.1186/s13561-023-00430-1.
- 505 10. International Vaccine Access Center, World Health Organization. *Results of COVID-*
506 *19 Vaccine Effectiveness Studies: An Ongoing Systematic Review*. 2022.
- 507 11. Bilgin GM, Lokuge K, Jabbie E, Munira SL, Glass K. COVID-19 vaccination
508 strategies in settings with limited rollout capacity: a mathematical modelling case study in
509 Sierra Leone. [preprint] available at Research Square. 2023. doi: 10.21203/rs.3.rs-
510 2460525/v1.
- 511 12. World Health Organization. *Therapeutics and COVID-19: living guideline*, 13 January
512 2023. Geneva: World Health Organization, 2023 Contract No.: WHO/2019-
513 nCoV/therapeutics/2023.1.
- 514 13. Robinson LA, Eber MR, Hammitt JK. Valuing COVID-19 Morbidity Risk Reductions.
515 *Journal of Benefit-Cost Analysis*. 2022;13(2):247-68. doi: 10.1017/bca.2022.11.
- 516 14. *World Population Prospects 2019*. 2019 [Cited 26/11/2021]. Available from:
517 <https://population.un.org/wpp/Download/Standard/Mortality/>.
- 518 15. GAVI. *The List of AMC-Eligible Economies 2021* [Cited 15/03/2023]. Available from:
519 <https://www.gavi.org/gavi-covax-amc>.
- 520 16. United Nation's Children's Fund. *COVID-19 Market Dashboard 2022* [Cited
521 15/12/2022]. Available from: <https://www.unicef.org/supply/covid-19-market-dashboard>.
- 522 17. Sim SY, Watts E, Constenla D, Huang S, Brenzel L, Patenaude BN. Costs of
523 Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From
524 2011 to 2030. *Value Health*. 2021;24(1):70-7. doi: 10.1016/j.jval.2020.07.010.
- 525 18. Papua New Guinea National Department of Health. *Comprehensive EPI Multi-Year*
526 *Plan for National Immunization Programme 2016-2020*. 2016.

- 527 19. Ministry of Health. A Comprehensive Multi Year Plan 2016-2020: the national
528 immunization program in Timor-Leste. 2015.
- 529 20. Kementerian Kesehatan Republik Indonesia. Comprehensive Multi Year Plan
530 National Immunization Program Indonesia, 2020-2024. 2019.
- 531 21. Mow M, Thean LJ, Parnaby M, Mani J, Rafai E, Sahukhan A, et al. Costs of mass
532 drug administration for scabies in Fiji. *PLOS Neglected Tropical Diseases*.
533 2022;16(2):e0010147. doi: 10.1371/journal.pntd.0010147.
- 534 22. World Health Organization. Immunization dashboard 2023 [Cited 05/05/2023].
535 Available from: <https://immunizationdata.who.int/index.html>.
- 536 23. World Health Organization. Seasonal influenza vaccine use in low and middle
537 income countries in the tropics and subtropics: a systematic review. Geneva: World Health
538 Organization, 2015 9789241565097.
- 539 24. Lazarus JV, Abdool Karim SS, van Selm L, Doran J, Batista C, Ben Amor Y, et al.
540 COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical
541 steps. *BMJ Global Health*. 2022;7(4):e009010. doi: 10.1136/bmjgh-2022-009010.
- 542 25. World Health Organization. Monitoring vaccine wastage at country level : guidelines
543 for programme managers. Geneva: World Health Organization; 2005.
- 544 26. Manas Mishra. U.S. to buy 10 mln courses of Pfizer's COVID-19 pill for \$5.3 bln 2021
545 [Cited 17/03/2023]. Available from: [https://www.reuters.com/business/healthcare-
546 pharmaceuticals/us-govt-buy-10-mln-courses-pfizers-covid-19-pill-529-bl-2021-11-18/](https://www.reuters.com/business/healthcare-pharmaceuticals/us-govt-buy-10-mln-courses-pfizers-covid-19-pill-529-bl-2021-11-18/).
- 547 27. Malaysian Health Technology Assessment Section. PROTEASE INHIBITORS
548 (PAXLOVID®) – ORAL TREATMENT FOR COVID-19 (updated). 2022.
- 549 28. Press release: CHAI announces agreements with leading generic manufacturers to
550 make affordable COVID-19 treatment available in low- and middle-income countries. 2022
551 [Cited 17/03/2023]. Available from: [https://www.clintonhealthaccess.org/news/chai-
554 announces-agreements-with-leading-generic-manufacturers-to-make-affordable-covid-19-
555 treatment-available-in-low-and-middle-income-countries/](https://www.clintonhealthaccess.org/news/chai-
552 announces-agreements-with-leading-generic-manufacturers-to-make-affordable-covid-19-
553 treatment-available-in-low-and-middle-income-countries/)
- 554 29. Bhattarai S, Chee H-Y, Japri A, Wiyarta E, Anderson BD. The Epidemiology of
555 Human Respiratory Viruses in Indonesia: A Systematic Review. *SSRN Electronic Journal*.
556 2022. doi: 10.2139/ssrn.4205782.
- 557 30. Menkir TF, Donnelly CA. The impact of repeated rapid test strategies on the
558 effectiveness of at-home antiviral treatments for SARS-CoV-2. *Nature Communications*.
559 2022;13(1):5283. doi: 10.1038/s41467-022-32640-2.
- 560 31. United Nation's Children's Fund. COVID-19 vaccine price data 2023 [Cited
561 15/03/2023]. Available from: [https://www.unicef.org/supply/documents/covid-19-vaccine-
562 price-data](https://www.unicef.org/supply/documents/covid-19-vaccine-
562 price-data).
- 563 32. COVAX. Costs of delivering COVID-19 vaccine in 92 AMC countries. 2021.

- 564 33. United Nation's Children's Fund. Syringe and safety box bundles price data 2022
565 [Cited 15/03/2023]. Available from: [https://www.unicef.org/supply/documents/syringe-and-](https://www.unicef.org/supply/documents/syringe-and-safety-box-bundles-price-data)
566 [safety-box-bundles-price-data](https://www.unicef.org/supply/documents/syringe-and-safety-box-bundles-price-data).
- 567 34. World Health Organization. Guidelines for estimating costs of introducing new
568 vaccines into the national immunization system. Geneva: World Health Organization; 2002.
- 569 35. Insitute for Clinical and Economic Review. Special Assessment of Outpatient
570 Treatments for COVID-19:Final Evidence Report and Meeting Summary. 2022.
- 571 36. Jo Y, Kim SB, Radnaabaatar M, Huh K, Yoo JH, Peck KR, et al. Model-based cost-
572 effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea. *Epidemiol Health*.
573 2022;44:e2022034. doi: 10.4178/epih.e2022034.
- 574 37. Savinkina A, Gonsalves G, Ross JS, Paltiel AD. Determining population-level
575 allocation strategies for COVID-19 treatments in the United States using a quantitative
576 framework, a case study using nirmatrelvir/ritonavir. *medRxiv*. 2022:2022.08.04.22278431.
577 doi: 10.1101/2022.08.04.22278431.
- 578 38. Albarqouni L, Palagama S, Chai J, Sivananthajothy P, Pathirana T, Bakhit M, et al.
579 Overuse of medications in low- and middle-income countries: a scoping review. *Bulletin of*
580 *the World Health Organization*. 2023;101(1):36-61D. doi: 10.2471/BLT.22.288293.
- 581 39. United Nation's Children's Fund. Rapid Tests 2023 [Cited 17/03/2023]. Available
582 from: [https://supply.unicef.org/all-materials/covid-diagnostic-test/serological-tests/rapid-](https://supply.unicef.org/all-materials/covid-diagnostic-test/serological-tests/rapid-tests.html)
583 [tests.html](https://supply.unicef.org/all-materials/covid-diagnostic-test/serological-tests/rapid-tests.html).
- 584 40. World Health Organization. WHO-CHOICE estimates of cost for inpatient and
585 outpatient health service delivery. 2021.
- 586 41. Nugraha RR, Pratiwi MA, Al-Faizin RE, Permana AB, Setiawan E, Farianty Y, et al.
587 Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims
588 data of COVID-19 in 2020-2021. *Health Economics Review*. 2022;12(1):45. doi:
589 10.1186/s13561-022-00392-w.
- 590 42. Mielke N, Johnson S, Bahl A. Boosters reduce in-hospital mortality in patients with
591 COVID-19: An observational cohort analysis. *The Lancet Regional Health - Americas*.
592 2022;8:100227. doi: 10.1016/j.lana.2022.100227.
- 593 43. Lee SW, Ma D, Davoodian A, Ayutyanont N, Werner B. COVID-19 vaccination
594 decreased COVID-19 hospital length of stay, in-hospital death, and increased home
595 discharge. *Preventive Medicine Reports*. 2023;32:102152. doi:
596 10.1016/j.pmedr.2023.102152.
- 597 44. Bruni A, Longhini F, Macheda S, Biamonte E, Pasqua P, Neri G, et al.
598 Characteristics of unvaccinated and vaccinated critically ill COVID-19 patients in calabria
599 region (Italy): A retrospective study. *Front Med (Lausanne)*. 2022;9. doi:
600 10.3389/fmed.2022.1042411.

- 601 45. de Broucker G, Sim SY, Brenzel L, Gross M, Patenaude B, Constenla DO. Cost of
602 Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic
603 Review of Cost-of-Illness Studies. *PharmacoEconomics*. 2020;38(10):1071-94. doi:
604 10.1007/s40273-020-00940-4.
- 605 46. World Health Organization. WHO guide for standardization of economic evaluations
606 of immunization programmes. Geneva: World Health Organization, 2019 Contract No.:
607 WHO/IVB/19.10.
- 608 47. International Labour Organization. Data 2023 [Cited 01/06/2023]. Available from:
609 <https://ilostat.ilo.org/data/>.
- 610 48. Jacobsen PA, Andersen MP, Gislason G, Phelps M, Butt JH, Køber L, et al. Return
611 to work after COVID-19 infection – A Danish nationwide registry study. *Public Health*.
612 2022;203:116-22. doi: 10.1016/j.puhe.2021.12.012.
- 613 49. Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2
614 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. *The Lancet*
615 *Respiratory Medicine*. 2022;10(9):863-76. doi: 10.1016/S2213-2600(22)00126-6.
- 616 50. Aben B, Kok RN, de Wind A. Return-to-work rates and predictors of absence
617 duration after COVID-19 over the course of the pandemic. *Scandinavian Journal of Work,*
618 *Environment & Health*. 2023;(3):182-92. doi: 10.5271/sjweh.4077.
- 619 51. Marella M, Busija L, Islam FMA, Devine A, Fotis K, Baker SM, et al. Field-testing of
620 the rapid assessment of disability questionnaire. *BMC Public Health*. 2014;14(1):900. doi:
621 10.1186/1471-2458-14-900.
- 622 52. Catharina YP, Kathryn EL, Yunita W, Aaron DS, Amalya M, Angela DI, et al.
623 Healthcare-seeking behaviors for acute respiratory illness in two communities of Java,
624 Indonesia: a cross-sectional survey. *Journal of Epidemiology and Global Health*.
625 2016;6(2):77-86. doi: 10.1016/j.jegh.2016.01.002.
- 626 53. Zwi A, Blignault I, Glazebrook D, Correia V, Bateman-Steel C, Ferreira E, et al.
627 Timor-Leste Health Care Seeking Behaviour Study, Final Report 2009.
- 628 54. Wang Y, Zhao D, Chen X, Liu X, Xiao W, Feng L. The effect of nirmatrelvir-ritonavir
629 on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron
630 variants. *Influenza and Other Respiratory Viruses*. 2023;17(2):e13095. doi:
631 10.1111/irv.13095.
- 632 55. WHO recommends highly successful COVID-19 therapy and calls for wide
633 geographical distribution and transparency from originator. 2022; [Cited 17/03/2023].
634 Available from: [https://www.who.int/news/item/22-04-2022-who-recommends-highly-](https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator)
635 [successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-](https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator)
636 [from-originator](https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator)

- 637 56. Medicines Patent Pool. Nirmatrelvir, 2021 [Cited 17/03/2023]. Available from:
638 <https://medicinespatentpool.org/licence-post/pf-07321332>.
- 639 57. World Health Organization. ACT-Accelerator Outcomes Report, 2020-22. 2022.
- 640 58. Fu Y, Zhao J, Han P, Zhang J, Wang Q, Wang Q, et al. Cost-effectiveness of
641 COVID-19 vaccination: A systematic review. *Journal of Evidence-Based Medicine*.
642 2023;16(2):152-65. doi: 10.1111/jebm.12525.
- 643 59. Sirison K, Nittayasoot N, Techasuwan R, Cetthakrikul N, Suphanchaimat R. Cost-
644 Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the
645 Period of Omicron Variant Predominance. *Tropical Medicine and Infectious Disease*. 2023;
646 8(2).
- 647 60. Li R, Liu H, Fairley CK, Zou Z, Xie L, Li X, et al. Cost-effectiveness analysis of
648 BNT162b2 COVID-19 booster vaccination in the United States. *International Journal of*
649 *Infectious Diseases*. 2022;119:87-94. doi: 10.1016/j.ijid.2022.03.029.
- 650 61. Li R, Liu H, Fairley CK, Ong JJ, Guo Y, Lu P, et al. mRNA-based COVID-19 booster
651 vaccination is highly effective and cost-effective in Australia. *Vaccine*. 2023;41(15):2439-46.
652 doi: 10.1016/j.vaccine.2023.01.075.
- 653 62. Savinkina A, Paltiel AD, Ross JS, Gonsalves G. Population-Level Strategies for
654 Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. *Open Forum Infectious*
655 *Diseases*. 2022;9(12):ofac637. doi: 10.1093/ofid/ofac637.
- 656 63. Wai AK-C, Chan CY, Cheung AW-L, Wang K, Chan SC-L, Lee TT-L, et al.
657 Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital
658 admissions and related avoidable healthcare system cost among high-risk patients with mild
659 to moderate COVID-19. *The Lancet Regional Health – Western Pacific*. 2023;30. doi:
660 10.1016/j.lanwpc.2022.100602.
- 661 64. Edoka I, Drake T, Baker P, Ndembi N, Tajudeen R, Asfaw E, et al. A cost-
662 effectiveness analysis of Molnupiravir and Paxlovid in three African countries. *medRxiv*.
663 2023:2023.07.05.23292205. doi: 10.1101/2023.07.05.23292205.

664

665 **Supporting information**

666 **File S1. Supplementary Material.** (PDF) Additional detail on the underlying dynamic
667 transmission model (S1), cost-effectiveness parameter estimates (S2), a breakdown of the
668 results (S3), and results for additional scenario analysis (S4).




Figure 1






Figure 2


Fiji




Indonesia



Papua New Guinea



Timor-Leste



lower estimate upper estimate

Figure 3